Physician profile
Jacob Lang
NPI 1053345835
$264,125.97
in general payments reported to CMS, 2019-2025
31 companies · $89K in 2025
The $89K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $13K · 2021: $20K · 2022: $26K · 2023: $45K · 2024: $49K · 2025: $89K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $89K · Consulting Fee: $57K · Travel and Lodging: $18K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $12K · Food and Beverage: $4,596 · Honoraria: $2,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $89,109.05 |
| Consulting Fee | $57,250.00 |
| Travel and Lodging | $17,521.03 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $12,150.00 |
| Food and Beverage | $4,595.96 |
| Honoraria | $2,550.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $70,232.92 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $51,412.76 | 2019-2025 | Cequa |
| Dompe US, INC. | $19,537.62 | 2022-2025 | Oxervate |
| Alcon Vision LLC | $18,052.34 | 2019-2025 | Tryptyr, Eysuvis, Rocklatan |
| Sparca LTD | $17,600.00 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $16,142.58 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $14,918.22 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Oyster Point Pharma, INC. | $13,367.12 | 2022-2024 | Tyrvaya |
| Abbvie INC. | $10,189.06 | 2022-2025 | |
| Horizon Therapeutics Plc | $6,642.97 | 2019-2023 | Tepezza |
| Shire North American Group INC | $4,762.14 | 2019 | |
| Alcon Research LLC | $4,736.05 | 2019-2025 | Tryptyr |
| Allergan, INC. | $3,784.32 | 2019-2021 | |
| Thea Pharma INC. | $3,524.01 | 2023-2024 | Iyuzeh |
| Sight Sciences, INC. | $2,062.53 | 2019-2025 | Tearcare System |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $1,837.79 | 2023-2025 | Clarus, Forum, Cirrus Hd-Oct |
| Carl Zeiss Meditec USA, INC. | $1,490.96 | 2024-2025 | Cirrus Hd-Oct, Humphrey Hfa, Iolmaster 700 |
| Aerie Pharmaceuticals, INC. | $1,082.96 | 2019 | |
| Kala Pharmaceuticals, INC. | $1,033.83 | 2021 | |
| Ocular Therapeutix, INC. | $526.53 | 2019-2021 | |
| Tearlab Corp | $522.94 | 2023-2024 | Tearlab Osmolarity System, Scoutpro Osmolarity System |
| Biotissue Holdings INC. | $162.67 | 2024-2025 | |
| Quidel Corporation | $143.56 | 2021-2022 | |
| Lumibird Medical INC. | $103.20 | 2025 | |
| Glaukos Corporation | $75.24 | 2025 | Idosetr |
| Valley Contax, INC. | $60.00 | 2019 | |
| Rxsight INC | $32.01 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Astellas Pharma US INC | $26.08 | 2023 | |
| Mallinckrodt Hospital Products INC. | $25.57 | 2025 | Acthar |
| Harrow Eye, LLC | $20.47 | 2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $17.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Lang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.